Clinical Trial Update: Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting Insulin

View source ↗

Summary

Novo Nordisk completed a patient preference study using a discrete choice experiment to inform its long-acting insulin development for Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tresiba (insulin degludec)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Type-2 Diabetes Mellitus (T2DM) | Status: COMPLETED